The company’s prospects look promising, with the growing injectables pipeline in the US and better portfolio mix

Despite good September quarter earnings, the stock of Aurobindo Pharma plummeted around 13 per cent after the announcement of results. The fall in the stock price was likely due to the gloomy near-term growth outlook of the company and also the weak sentiment that has engulfed the pharma sector due to regulatory clampdown. However, investors with a long-term horizon can consider buying the sto...